Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
SALT LAKE CITY - SINTX Technologies, Inc. (NASDAQ: SINT), a micro-cap company with a market value of $6.73 million and annual revenue of $2.57 million, known for its advanced ceramics in medical devices, has announced the formation of a new subsidiary, SINTX Agribiotech, Inc., to explore agricultural applications of its silicon nitride technology. According to InvestingPro data, the company maintains a healthy gross profit margin of 67.54%. The company’s recent acquisition of International Patent No. 7635292, alongside U.S. Patent No. 11,591,217, marks its entry into the antimicrobial agribiotech market. While SINTX’s stock has experienced significant volatility, falling over 83% in the past year, the company maintains more cash than debt on its balance sheet, according to InvestingPro analysis.
This strategic move leverages the antimicrobial properties of silicon nitride, particularly in plant protection. Studies have shown that this material can significantly reduce the growth of Plasmopara viticola, a pathogen that causes grapevine downy mildew, by 80-90%. Unlike traditional fungicides, silicon nitride offers a broad-spectrum antimicrobial action without harming plant tissue or the environment, which is increasingly important as regulatory restrictions on copper-based fungicides tighten.
SINTX’s independent agribiotech subsidiary will focus on developing and commercializing agricultural and environmental technologies, with an initial emphasis on viticulture. The company plans to deploy its silicon nitride technology in various agricultural settings, including vineyards and hydroponic facilities.
The global antimicrobial fertilizer and crop protection market, where SINTX intends to position its technology, is expected to grow to $10.36 billion by 2030. The company aims to meet the industry’s demand for sustainable and high-performance crop protection solutions.
Eric Olson, Chairman and CEO of SINTX, emphasized the potential of their silicon nitride in agriculture, stating that it "doesn’t just inactivate pathogens—it can also prevent most infections altogether."
SINTX Technologies continues to focus on advancing silicon nitride for medical applications while exploring its utility in adjacent sectors. The company’s products have been used in human implants since 2008, and it remains a global leader in the research, development, and manufacturing of the material.
The information in this article is based on a press release statement from SINTX Technologies. InvestingPro subscribers have access to 12 additional investment tips and comprehensive financial metrics for SINTX, including detailed Fair Value analysis and financial health scores, helping investors make more informed decisions about emerging opportunities in the biotech sector.
In other recent news, SINTX Technologies has reported significant financial improvements for the first quarter ending March 31, 2025, with cash reserves nearly doubling to $6.5 million, aided by a $5.0 million private placement. The company has also reduced its operating cash burn from $2.7 million in Q1 2024 to $1.3 million in Q1 2025 through strategic cost optimization. SINTX has announced a strategic shift towards the medical device sector, focusing on silicon nitride-based products, and has initiated new research and development programs in this area. In a leadership update, Eric Olson has been appointed as the new Chairman of the Board, succeeding Dr. Sonny Bal, who will remain a board member. The company has also reshaped its Board of Directors, adding five new directors with extensive experience in the medical device industry. SINTX recently published a study highlighting the biomechanical benefits of silicon nitride in spinal surgery, emphasizing its superiority over traditional materials like PEEK and titanium. The company continues to explore partnerships and licensing opportunities to expand its market presence in the medical sector. These developments underscore SINTX’s commitment to leveraging its advanced ceramics expertise for growth in the healthcare industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.